Integrated Wealth Concepts LLC Has $1.09 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Integrated Wealth Concepts LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 8.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 6,665 shares of the company’s stock after selling 606 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Zoetis were worth $1,086,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Callahan Advisors LLC lifted its position in shares of Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after buying an additional 6,221 shares during the last quarter. CIBC Asset Management Inc boosted its stake in shares of Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Pensionfund Sabic grew its holdings in shares of Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after purchasing an additional 4,000 shares during the last quarter. Schroder Investment Management Group grew its holdings in shares of Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock valued at $40,036,000 after purchasing an additional 6,169 shares during the last quarter. Finally, PFW Advisors LLC acquired a new position in Zoetis during the 4th quarter worth approximately $1,764,000. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 in the last quarter. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research reports. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Stifel Nicolaus lowered their target price on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. Piper Sandler increased their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $214.40.

Zoetis Price Performance

ZTS stock opened at $155.53 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market cap of $69.39 billion, a price-to-earnings ratio of 28.43, a PEG ratio of 2.78 and a beta of 0.92. The company’s fifty day simple moving average is $158.81 and its 200 day simple moving average is $167.98. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.29%. Zoetis’s dividend payout ratio is currently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.